The weight loss drug is so profitable that its parent company, Danish health care giant Novo Nordisk, is propping up Denmark’s entire economy. It’s poised to transform America’s too.
This episode was produced by Victoria Chamberlin edited by Jolie Myers, fact-checked by Kim Eggleston, engineered by Rob Byers, and hosted by Noel King.
Transcript at vox.com/to ... Show More
Oct 28
The future of MAGA is... Nixon?
MAGA-aligned conservatives, including Vice President JD Vance, are trying to rehabilitate Richard Nixon's image. That's evidence of where they want to take their party. This episode was produced by Dustin DeSoto, edited by Amina Al-Sadi, fact-checked by Gabriel Dunatov, engineere ... Show More
27m 44s
Jun 2024
The weight-loss drug revolution
Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ... Show More
17m 28s
Jun 2024
Denmark and the Novo Nordisk effect
<p>In the first of a two-part series, in collaboration with The Food Chain, we look at the impact of the success of weight-loss drug manufacturer Novo Nordisk on the small country of Denmark. </p><p>The Scandinavian nation is where the company is based, and with a population of l ... Show More
17m 29s
Dec 2024
Deep Dive: The Gold Rush to Cure the Obesity Epidemic
<p>GLP-1 weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound, are credited with reversing obesity trends in the U.S. for the first time in decades, according to a new study in the Journal of the American Medical Association. The episode highlights the rapid ... Show More
8m 47s